Guggenheim Initiates Coverage On ZimVie with Neutral Rating
Guggenheim analyst Chris Pasquale initiates coverage on ZimVie (NASDAQ:ZIMV) with a Neutral rating.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday.